Clinical Improvement by EquMet in patient with type 2 diabetes (T2D) and poor compliance of diet therapy

Bando H, Okada M, Iwatsuki N, Sakamoto K and Ogawa T

Published on: 2023-05-25

Abstract

The case is 75-year-old male with previous hypertension and dyslipidemia. For recent 10 years, he has been treated for Type 2 diabetes (T2D), slight cerebral vascular accident (CVA) and mild cognitive impairment (MCI). His clinical problem included poor compliance of diet therapy. After he started EquMet (Equa + Metformin), his glucose variability became stable. HbA1c value decreased from 9.1% to 6.7% for 18 months. EquMet is provided twice a day, in which it shows medical efficacy of decreasing nocturnal blood glucose surge. This effect may contribute clinical improvement of glucose variability. His clinical progress will be followed-up with attention.